SABS - SAB Biotherapeutics, Inc. Stock Price, Fair Value and News

2.84USD-0.02 (-0.70%)Market Closed

Market Summary

USD2.84-0.02

Market Closed

-0.70%

SABS Stock Price

View Fullscreen

SABS RSI Chart

SABS Valuation

Market Cap

26.4M

Price/Earnings (Trailing)

-0.66

Price/Sales (Trailing)

10.14

EV/EBITDA

-0.36

Price/Free Cashflow

-0.76

SABS Price/Sales (Trailing)

SABS Profitability

EBT Margin

-1531.84%

Return on Equity

-75.47%

Return on Assets

-55.86%

Free Cashflow Yield

-130.96%

SABS Fundamentals

SABS Revenue

Revenue (TTM)

2.6M

Rev. Growth (Yr)

62.55%

Rev. Growth (Qtr)

209.69%

SABS Earnings

Earnings (TTM)

-39.9M

Earnings Growth (Yr)

31.66%

Earnings Growth (Qtr)

78.01%

Breaking Down SABS Revenue

Last 7 days

-3.2%

Last 30 days

-6.1%

Last 90 days

-35.1%

How does SABS drawdown profile look like?

SABS Financial Health

Current Ratio

5.65

Debt/Equity

0.01

Debt/Cashflow

-63.26

SABS Investor Care

Buy Backs (1Y)

81.69%

Diluted EPS (TTM)

-9.36

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.6M	0	0	0
2023	12.7M	6.4M	4.1M	2.2M
2022	55.8M	43.9M	32.8M	23.9M
2021	56.6M	58.1M	59.5M	60.9M
2020	0	0	29.3M	55.2M
2019	0	0	0	3.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

CEO	Dr. Eddie Joe Sullivan Ph.D.
WEBSITE	sabbiotherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	56

SAB Biotherapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for SAB Biotherapeutics, Inc.? What does SABS stand for in stocks?

SABS is the stock ticker symbol of SAB Biotherapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SAB Biotherapeutics, Inc. (SABS)?

As of Thu Jul 25 2024, market cap of SAB Biotherapeutics, Inc. is 26.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SABS stock?

You can check SABS's fair value in chart for subscribers.

Is SAB Biotherapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether SABS is over valued or under valued. Whether SAB Biotherapeutics, Inc. is cheap or expensive depends on the assumptions which impact SAB Biotherapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SABS.

What is SAB Biotherapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, SABS's PE ratio (Price to Earnings) is -0.66 and Price to Sales (PS) ratio is 10.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SABS PE ratio will change depending on the future growth rate expectations of investors.